专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08680237B2 Immunoglobulin constant region FC receptor binding agents 有权
标题翻译：免疫球蛋白恒定区FC受体结合剂
公开(公告)号：US08680237B2
公开(公告)日：2014-03-25
申请号：US12602609
申请日：2008-05-30
申请人： Scott E. Strome , Dan H. Schulze , David S. Block , Henrik Olsen
发明人： Scott E. Strome , Dan H. Schulze , David S. Block , Henrik Olsen
IPC分类号： C07K1/00 , A61K35/14 , C07K16/00 , C12P21/08
CPC分类号： C07K16/00 , A61K2039/505 , A61K2039/54 , A61K2039/57 , C07K16/065 , C07K16/18 , C07K16/28 , C07K16/283 , C07K16/2863 , C07K16/32 , C07K2317/35 , C07K2317/41 , C07K2317/50 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/528 , C07K2317/53 , C07K2317/55 , C07K2317/71 , C07K2317/72 , C07K2317/73 , C07K2317/92 , C07K2318/00 , C07K2319/00 , C07K2319/30 , G01N33/5047 , G01N2500/10 , Y02A50/412
摘要： IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
摘要翻译： IVIG替代化合物衍生自免疫活性仿生物的重组和/或生物化学产生。然后在体外筛选这些置换化合物以评估每种替代化合物调节免疫功能的效率。选择特定的替代化合物用于进一步的体内验证和剂量/给药优化。最后，替代化合物用于治疗广泛的疾病，包括炎性和自身免疫疾病。

2. 发明申请

US20100239633A1 IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS 有权
标题翻译：免疫球蛋白恒定区FC受体结合剂
公开(公告)号：US20100239633A1
公开(公告)日：2010-09-23
申请号：US12602609
申请日：2008-05-30
申请人： Scott E. Strome , Dan H. Schulze , David S. Block
发明人： Scott E. Strome , Dan H. Schulze , David S. Block
IPC分类号： A61K9/70 , C07K16/00 , A61K39/395 , G01N33/53 , C12N5/071 , C12N5/078 , A61K9/00 , A61K9/127 , A61P35/00 , A61P31/12 , A61P31/04 , A61P31/22 , A61P33/06 , A61P37/02 , A61P25/28
CPC分类号： C07K16/00 , A61K2039/505 , A61K2039/54 , A61K2039/57 , C07K16/065 , C07K16/18 , C07K16/28 , C07K16/283 , C07K16/2863 , C07K16/32 , C07K2317/35 , C07K2317/41 , C07K2317/50 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/528 , C07K2317/53 , C07K2317/55 , C07K2317/71 , C07K2317/72 , C07K2317/73 , C07K2317/92 , C07K2318/00 , C07K2319/00 , C07K2319/30 , G01N33/5047 , G01N2500/10 , Y02A50/412
摘要： IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
摘要翻译： IVIG替代化合物衍生自免疫活性仿生物的重组和/或生物化学产生。然后在体外筛选这些置换化合物以评估每种替代化合物调节免疫功能的效率。选择特定的替代化合物用于进一步的体内验证和剂量/给药优化。最后，替代化合物用于治疗广泛的疾病，包括炎性和自身免疫性疾病。

3. 发明授权

US08747833B2 B7-H1 and methods of diagnosis, prognosis, and treatment of cancer 有权
标题翻译： B7-H1和癌症的诊断，预后和治疗方法
公开(公告)号：US08747833B2
公开(公告)日：2014-06-10
申请号：US13012063
申请日：2011-01-24
申请人： Lieping Chen , Scott E. Strome , Eugene D. Kwon
发明人： Lieping Chen , Scott E. Strome , Eugene D. Kwon
IPC分类号： A61K38/19
CPC分类号： C07K16/2803 , A61K38/2013 , A61K38/2026 , A61K38/2066 , A61K38/208 , A61K38/2086 , A61K38/212 , A61K38/215 , A61K38/217 , A61K2039/505 , C07K16/2827 , C07K16/30 , C07K2317/24 , C07K2317/76 , C12N15/113 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2320/30 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N33/5088 , G01N33/5091 , G01N33/56972 , G01N33/57407 , G01N33/57438 , G01N33/57484
摘要： The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
摘要翻译：本发明的特征在于通过评估来自具有或被怀疑患有癌症的受试者的组织中的B7-H1表达，以及干扰B7-H1受体相互作用的试剂的治疗方法，可能地选择候选对象的方法受益于癌症免疫治疗，以及抑制B7-H1表达的方法。

4. 发明申请

US20120225043A1 Enhancement of Immune Responses By 4-1BB-Binding Agents 有权
标题翻译： 4-1BB结合剂增强免疫反应
公开(公告)号：US20120225043A1
公开(公告)日：2012-09-06
申请号：US13426151
申请日：2012-03-21
申请人： Lieping Chen , Scott E. Strome
发明人： Lieping Chen , Scott E. Strome
IPC分类号： A61K35/14 , A61P35/00 , A61P33/02 , A61P31/04 , A61P31/10 , A61P31/00 , A61P31/12
CPC分类号： A61K39/39 , A61K39/00 , A61K39/0011 , A61K39/12 , A61K2039/505 , A61K2039/5152 , A61K2039/5154 , A61K2039/5158 , A61K2039/55516 , A61K2039/55522 , A61K2039/585 , C07K16/2878 , C12N2710/20034
摘要： This invention features methods of enhancing immune responses in mammalian subjects and in vitro methods of enhancing the response of a T cell. Also embodied by the invention are methods of receiving and preventing the induction of energy in T cells.
摘要翻译：本发明的特征在于增强哺乳动物受试者的免疫应答的方法和体外增强T细胞应答的方法。本发明还体现了接收和预防T细胞中能量诱导的方法。

5. 发明申请

US20120027759A1 METHODS OF ENHANCING T CELL RESPONSIVENESS 审中-公开
标题翻译：增强细胞应答的方法
公开(公告)号：US20120027759A1
公开(公告)日：2012-02-02
申请号：US12835410
申请日：2010-07-13
申请人： Lieping Chen , Scott E. Strome
发明人： Lieping Chen , Scott E. Strome
IPC分类号： A61K39/395 , A61P37/04 , A61P35/00 , C12N5/09 , A61K38/17
CPC分类号： C07K16/2827 , A61K39/0011 , A61K2039/515 , A61K2039/5156 , A61K2039/5158 , C07K2319/00 , C07K2319/30 , C12N5/0636 , C12N2501/23 , C12N2501/51
摘要： The invention features methods of enhancing the responsiveness of a T cell. Such methods involve interfering with the interaction between a T cell and a B7-H1 molecule.
摘要翻译：本发明的特征在于提高T细胞的反应性的方法。这种方法涉及干扰T细胞和B7-H1分子之间的相互作用。

6. 发明授权

US08263560B2 HPV 16 peptide vaccine for head and neck cancer 有权
标题翻译：用于头颈部癌症的HPV16肽疫苗
公开(公告)号：US08263560B2
公开(公告)日：2012-09-11
申请号：US11837737
申请日：2007-08-13
申请人： Scott E. Strome , Esteban Celis
发明人： Scott E. Strome , Esteban Celis
IPC分类号： A61K38/16 , A61P31/00
CPC分类号： C07K14/4748 , A61K39/0011 , A61K39/12 , A61K2039/5154 , A61K2039/6075 , A61K2039/645 , C07K14/005 , C07K2319/01 , C07K2319/50 , C12N2710/20022 , C12N2710/20034 , C12N2740/16322
摘要： The present invention relates to Trojan antigens, and immunogenic compositions comprising the Trojan antigens. The present invention also relates to methods of generating an immune response in a subject using the Trojan antigens or immunogenic compositions. The present invention further relates to methods of treating squamous cell carcinoma of the head and neck (SCCHN) using the Trojan antigens and immunogenic compositions of the present invention.
摘要翻译：本发明涉及木马抗原和包含特洛伊木霉抗原的免疫原性组合物。本发明还涉及使用特洛伊木马抗原或免疫原性组合物在受试者中产生免疫应答的方法。本发明还涉及使用本发明的特洛伊抗原和免疫原性组合物治疗头颈部鳞状细胞癌（SCCHN）的方法。

7. 发明申请

US20120058047A9 METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION 审中-公开
标题翻译：使用抗CD137抗体作为放射免疫疗法或放射免疫测定法的方法
公开(公告)号：US20120058047A9
公开(公告)日：2012-03-08
申请号：US12713731
申请日：2010-02-26
申请人： Scott E. Strome , Daniel Schindler , Lieping Chen , Harry M. Meade , Yann Echelard
发明人： Scott E. Strome , Daniel Schindler , Lieping Chen , Harry M. Meade , Yann Echelard
IPC分类号： A61K51/00 , A61P35/02 , A61P35/04 , A61P35/00
CPC分类号： A61K51/1096
摘要： The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred embodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.
摘要翻译：本发明涉及重组激动抗体抗人CD137及其糖基化变体的开发和使用方法。这些抗体作为有效减少实体瘤或其他癌症适应症并防止其复发的抗癌剂和/或免疫调节剂。预期抗体对其治疗有效的癌症类型还包括白血病和淋巴瘤。在优选的实施方案中，本发明的重组抗体在转基因动物的牛奶中制备并纯化。在本发明的另一个优选实施方案中，本发明的激动性抗CD137抗体可以与放射性核素缀合以用于放射免疫检测或放射免疫治疗目的，或与毒素结合以增强各种癌症的治疗性治疗。

8. 发明申请

US20110104049A1 METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION 审中-公开
标题翻译：使用抗CD137抗体作为放射免疫疗法或放射免疫测定法的方法
公开(公告)号：US20110104049A1
公开(公告)日：2011-05-05
申请号：US12713731
申请日：2010-02-26
申请人： Scott E. Strome , Daniel Schindler , Lieping Chen , Harry M. Meade , Yann Echelard
发明人： Scott E. Strome , Daniel Schindler , Lieping Chen , Harry M. Meade , Yann Echelard
IPC分类号： A61K51/00 , A61P35/00 , A61P35/02 , A61P35/04
CPC分类号： A61K51/1096
摘要： The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred embodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.
摘要翻译：本发明涉及重组激动抗体抗人CD137及其糖基化变体的开发和使用方法。这些抗体作为有效减少实体瘤或其他癌症适应症并防止其复发的抗癌剂和/或免疫调节剂。预期抗体对其治疗有效的癌症类型还包括白血病和淋巴瘤。在优选的实施方案中，本发明的重组抗体在转基因动物的牛奶中制备并纯化。在本发明的另一个优选实施方案中，本发明的激动性抗CD137抗体可以与放射性核素缀合以用于放射免疫检测或放射免疫治疗目的，或与毒素结合以增强各种癌症的治疗性治疗。

9. 发明授权

US07449300B2 Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells 有权
标题翻译：检测受活化T细胞介导的疾病或病理状况受试者B7-H1特异性抗体
公开(公告)号：US07449300B2
公开(公告)日：2008-11-11
申请号：US10719477
申请日：2003-11-21
申请人： Lieping Chen , Scott E. Strome
发明人： Lieping Chen , Scott E. Strome
IPC分类号： G01N33/53
CPC分类号： C07K16/2827 , A61K2039/505 , C07K2317/74
摘要： The invention provides methods of removing B7-H1-specific antibodies from a body fluid (e.g., blood), methods of diagnosing and treating diseases and pathological conditions mediated by activated T cells, methods for screening for compounds that inhibit binding of a B7-H1-specific antibody to B7-H1, and methods of designing compounds that inhibit binding of a B7-H1-specific antibody to B7-H1.
摘要翻译：本发明提供从体液（例如血液）中除去B7-H1特异性抗体的方法，诊断和治疗由活化的T细胞介导的疾病和病理状况的方法，筛选抑制B7-H1结合的化合物的方法 B7-H1的特异性抗体，以及设计抑制B7-H1特异性抗体与B7-H1结合的化合物的方法。

10. 发明授权

US6015419A Retractable surgical scalpel 失效
标题翻译：可伸缩手术刀
公开(公告)号：US6015419A
公开(公告)日：2000-01-18
申请号：US143833
申请日：1998-08-31
申请人： Scott E. Strome , Edward T. Joseph
发明人： Scott E. Strome , Edward T. Joseph
IPC分类号： A61B17/32
CPC分类号： A61B17/3211 , A61B2017/32113
摘要： A surgical instrument includes a hollow handle having an end slot and a side slot and a blade carrier securable to a scalpel blade and moveable between first and second positions relative to the handle. One of the first and second positions is an extended, in-use position wherein the scalpel blade extends out of the handle through the end slot. The other position is a retracted, non-use position wherein the scalpel blade is wholly disposed within the handle. At least one finger extends from the blade carrier and has a first contoured portion engageable, when the blade carrier is in the first position, with a second contoured portion of the handle. The first and second contoured portions are substantially complementary such that the finger must deflect to permit disengagement of the first contoured portion of the finger from the second contoured portion of the handle so that the blade carrier can be moved from the first position toward the second position. A locking cam is moveable between a locked position wherein the locking cam substantially inhibits deflection of the finger of the blade carrier and an unlocked position wherein the locking cam permits deflection of the finger of the blade carrier. A method of using this surgical instrument includes the steps of moving the locking cam to the unlocked position if the locking cam is in the locked position, moving the blade carrier from the first position to the second position or from the second position to the first position, and moving the locking cam to the locked position.
摘要翻译：手术器械包括具有端槽和侧槽的中空手柄，以及可固定至解剖刀刀片的刀片架，并可在相对于手柄的第一和第二位置之间移动。第一和第二位置中的一个是延伸的使用中的位置，其中解剖刀刀片通过端槽延伸出手柄。另一位置是缩回的非使用位置，其中解剖刀刀片完全设置在手柄内。至少一个手指从刀片托架延伸并具有当刀片托架处于第一位置时可与手柄的第二轮廓部分接合的第一轮廓部分。第一和第二轮廓部分是基本上互补的，使得手指必须偏转以允许手指的第一轮廓部分与手柄的第二轮廓部分脱离，使得叶片载体能够从第一位置向第二位置移动。锁定凸轮可在锁定位置之间移动，其中锁定凸轮基本上禁止叶片托架的手指的偏转和锁定凸轮允许叶片托架的手指偏转的解锁位置。使用该外科器械的方法包括以下步骤：如果锁定凸轮处于锁定位置，则将锁定凸轮移动到解锁位置，将刀架从第一位置移动到第二位置或从第二位置移动到第一位置，并将锁定凸轮移动到锁定位置。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式